Pharmacokinetic Study of ABT-126 in Healthy Volunteers | NCT00959634 | Trialant
CompletedInterventionalPhase 1Updated Nov 3, 2010
Pharmacokinetic Study of ABT-126 in Healthy Volunteers
ClinicalTrials.gov ID
NCT00959634
Lead Sponsor
AbbottINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1
Enrollment
20Actual
Last Update Posted
Nov 3, 2010Estimated
Start Date
Aug 2009
Primary Completion Date
Sep 2009Actual
Brief Summary
This is a study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and eliminated by the body of a healthy volunteer.
Healthy Volunteers
ABT-126
Placebo
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
Healthy male and female subjects between 18 and 50 years of age
If female, subject must be postmenopausal for at least 2 years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)
If male, subject must be surgically sterile (vasectomy) or agrees to use a barrier method (i.e., condom) of birth control starting on the first day of confinement until 30 days after the last study drug administration
Exclusion Criteria:
Requirement for any over-the-counter and/or prescription medication, vitamins and/or herbal supplements on a regular basis
History of diabetes, cancer (except basal cell carcinoma of the skin), or any clinically significant cardiovascular, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, neurologic or psychiatric disease or disorder